European Medicines Agency approvals of new medicines in September and October 2025. [PDF]
Sepodes B, Burgos JG, Thirstrup S.
europepmc +1 more source
Serum Soluble ST2 and IL-33 Levels in Finnish Patients With Juvenile Idiopathic Arthritis. [PDF]
Teräsjärvi J +6 more
europepmc +1 more source
Evaluation of Sleep Disturbances and Depression in Children with Juvenile Idiopathic Arthritis Using the Beck Depression Inventory and Child Sleep Disorder Scale: Relationship with Leukocyte and Neutrophil Counts. [PDF]
Dogantan S +4 more
europepmc +1 more source
Correction to: Quantifying hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-α inhibitors in juvenile idiopathic arthritis. [PDF]
europepmc +1 more source
Children's experiences of a support program during their first year with juvenile idiopathic arthritis : - Insights from qualitative interviews. [PDF]
Mördrup K +3 more
europepmc +1 more source
Integrative pharmacovigilance and AI-based framework uncovers potential drug triggers in juvenile idiopathic arthritis. [PDF]
Luo Q +9 more
europepmc +1 more source
Cross-Sectional and Longitudinal Immunoprofiling of Oligoarticular Juvenile Idiopathic Arthritis Reveals Different Patterns in Synovial Fluid and Plasma. [PDF]
Qu H +7 more
europepmc +1 more source
Juvenile Idiopathic Arthritis-The Rubik's Cube of Pediatric Rheumatology. [PDF]
Jones OY +3 more
europepmc +1 more source
Systemic juvenile idiopathic arthritis, with tinea capitis and peripheral eosinophilia: a case report. [PDF]
Alameen ABM +3 more
europepmc +1 more source
Impact of Concomitant Methotrexate Use and Prior Biologic Disease-Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial. [PDF]
Ruperto N +25 more
europepmc +1 more source

